[ad_1]
Gland Pharma on Monday stated it has obtained approval from the US well being regulator to market a generic treatment used to deal with breast most cancers. The corporate has obtained approval from the US Meals and Drug Administration (USFDA) for Eribulin Mesylate Injection (0.5 mg/mL single dose vial), it stated in a press release.
The product is predicted to be the primary generic approval out there, and the corporate expects to launch this product within the close to time period by its advertising companion, it added.
In line with IQVIA, the product has gross sales of round USD 92 million within the US for 12 months ending in February 2024.
The corporate stated it’s co-developing a number of complicated injectables, together with the product, with Orbicular Pharmaceutical Applied sciences Pvt Ltd.
Shares of Gland Pharma on Monday ended 5.59 per cent up at Rs 1,853.25 apiece on the BSE.
[ad_2]
Source link
